POMPANO BEACH

SKYX Announces First Quarter 2024 Corporate Update Call

Retrieved on: 
Thursday, May 9, 2024
Lighting

MIAMI, May 09, 2024 (GLOBE NEWSWIRE) -- SKYX Platforms Corp. (NASDAQ: SKYX) (d/b/a "SKYX Technologies"), a highly disruptive platform technology company with over 90 pending and issued patents globally, and over 60 lighting and home décor websites with a mission to make homes and buildings become safe-advanced and smart as the new standard, announced today that it will host a corporate update call and discuss first quarter 2024 financial results.

Key Points: 
  • MIAMI, May 09, 2024 (GLOBE NEWSWIRE) -- SKYX Platforms Corp. (NASDAQ: SKYX) (d/b/a "SKYX Technologies"), a highly disruptive platform technology company with over 90 pending and issued patents globally, and over 60 lighting and home décor websites with a mission to make homes and buildings become safe-advanced and smart as the new standard, announced today that it will host a corporate update call and discuss first quarter 2024 financial results.
  • The conference call will be held on Tuesday, May 14, 2024, at 4:30 pm Eastern Time.
  • SKYX Participating Members Will Include:

Mitigating Muscle Loss Becoming More Vital, Global Cancer Cachexia Market Projected to Reach $3.3 Billion in 2024

Retrieved on: 
Wednesday, May 8, 2024
MSD, PFS, FDA, Pfizer, MRNA, News, Atrophy, Weight loss, Doctor of Philosophy, Vaccine, University of Toronto, PFE, Medicinal chemistry, Medicine, Genome, Moderna, Diagnosis, AstraZeneca, Prevalence, GEJ, University, CPS, HER2, Food, OTC, IHC, Cachexia, Pneumococcal conjugate vaccine, Messenger, Quality of life, RSV, Patient, Facial muscles, Professor, Oncology, Trastuzumab, Research, Incidence, Fatigue, EPS, Neoplasm, MUSL, MRK, Tafamidis, Progression-free survival, PALM, PD-L1, COVID-19, Growth, Pharmaceutical industry

Cachexia is a medical condition known as ‘wasting syndrome’ that causes severe weight loss, muscle loss, and loss of body fats.

Key Points: 
  • Cachexia is a medical condition known as ‘wasting syndrome’ that causes severe weight loss, muscle loss, and loss of body fats.
  • The Cancer Cachexia market refers to the segment of the healthcare industry focused on addressing the multifaceted challenges associated with cachexia in cancer patients.
  • A report from Custom Market Insights projects that the global Cancer Cachexia Market is expected to record a CAGR of 5.1% from 2024 to 2033.
  • In 2024, the market size is projected to reach a valuation of USD 3.3 Billion.

SKYX to be a Main Event at TheRealDeal New York City Real-Estate Forum & Developer Showcase

Retrieved on: 
Tuesday, May 7, 2024
City, The Real Deal, Innovation, TRD, Lighting, Booth, Metropolitan Pavilion, Video game

SKYX will present its game changing smart home technology platform and products at Booth 2 and will host a management presentation at 3:30 pm at the Innovation Stage.

Key Points: 
  • SKYX will present its game changing smart home technology platform and products at Booth 2 and will host a management presentation at 3:30 pm at the Innovation Stage.
  • The Real Deal hosts and organizes the real estate industry’s largest events, including New York City, South Florida, and the Los Angeles Real Estate Showcase & Forums in addition to Future City, and TRD Brand Studio bespoke events.
  • As SKYX continues to enhance its market penetration, it will showcase its game-changing smart home platform technology to high-end real-estate developers and industry professionals.
  • Our technology enables an advanced and instant smart home solution that will significantly enhance real-estate value for both developers and homeowners.

Uranium Sector Expected to See a Run as Positive Momentum and Demand Builds

Retrieved on: 
Tuesday, May 7, 2024
Electronic document, STUD, Uranium, News, URL, Webcast, Radioactive decay, Knowledge, URG, Web browser, Forum, Probability, Cameco, FMC, Annual report, Stallion, TSX, Attention, Nuclear energy, Energy, Goldman Sachs, Energy & Fuels, System, Carbon, ANT, REUTERS, Marketing, G7, Miner, OTCQB, PALM, Encore, Anomaly, Mining, HMS, Q&A, Uranium mining

With the headlines and positive momentum in nuclear more generally, hedge funds and other commodity investors are back in the (uranium) sector.

Key Points: 
  • With the headlines and positive momentum in nuclear more generally, hedge funds and other commodity investors are back in the (uranium) sector.
  • A lot of it is done via physical funds, the easiest way to get exposure to uranium prices,” said Bram Vanderelst at trading firm Curzon Uranium.
  • And now, within our 2024 objectives, we remain focused on commencing production at the Alta Mesa Uranium Central Processing Plant.
  • "Energy Fuels maintained our momentum from 2023, by reporting continued profitability in Q1-2024, driven mainly by uranium.

Global Military Drone Market Expected to Reach $18 Billion By 2028 as U.S. Government Plays Crucial Role in Military Drone Industry

Retrieved on: 
Tuesday, May 7, 2024
ARK, Online, UAV, Group 1, Grumman, News, Partnership, AeroVironment, Convention (norm), RCAT, UAS, Defense, LMT, Aircraft, Lockheed Martin, Machine learning, Software, ATAK, NDAA, Special, Telephone, Radio, MANET, Ad hoc, Demonstration, SRR, Sony, Raytheon Technologies, Century, Government, Atmosphere, USD, FPV, PALM, Environment, General Atomics, Northrop Grumman, Technology company, Drone, Growth, Compound annual growth rate

According to a report from MarketsAndMarkets, the military drone market is poised to reach USD 18.2 billion by 2028, with a Compound Annual Growth Rate (CAGR) of 7.0% during the period from 2023 to 2028.

Key Points: 
  • According to a report from MarketsAndMarkets, the military drone market is poised to reach USD 18.2 billion by 2028, with a Compound Annual Growth Rate (CAGR) of 7.0% during the period from 2023 to 2028.
  • The report said: “The global race among nations to invest in drone technology has sparked a competitive environment.
  • This demand for more sophisticated drone capabilities is a key factor stimulating the expansion of the military drone market.
  • The MarketsAndMarkets report continued: “Based on operation mode, The military drone market is divided into remotely piloted, optionally piloted, and fully autonomous categories.

BioStem Technologies to Report First Quarter 2024 Financial Results on Tuesday, May 14, 2024

Retrieved on: 
Tuesday, May 7, 2024
OTC, Webcast

POMPANO BEACH, Fla., May 07, 2024 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTC: BSEM), a leading biotechnology company focused on the development, manufacture, and commercialization of placental derived allografts for advanced wound care, announced today that it plans to release its first quarter 2024 financial results post-market on Tuesday, May 14, 2024.

Key Points: 
  • POMPANO BEACH, Fla., May 07, 2024 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTC: BSEM), a leading biotechnology company focused on the development, manufacture, and commercialization of placental derived allografts for advanced wound care, announced today that it plans to release its first quarter 2024 financial results post-market on Tuesday, May 14, 2024.
  • BioStem will host a conference call and webcast at 4:30 pm ET on Tuesday, May 14, 2024.
  • The call will include a discussion of first quarter 2024 financial results and a corporate update.
  • The live and archived webcast of the call will also be available on the BioStem Technologies website under the Investors section or by following this link: https://events.q4inc.com/attendee/274186276

BioStem Technologies Granted Prioritized Examination for Wound Healing Patent

Retrieved on: 
Monday, May 6, 2024
OTC, United States patent law, Patent, Patient, Regenerative medicine, Pharmaceutical industry

POMPANO BEACH, Fla., May 06, 2024 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental derived allografts for advanced wound care, today announced that the United States Patent and Trademark Office (USPTO) has granted the Company’s request for Prioritized Examination for its application for U.S. Patent 18/290,914 titled STERILE HUMAN PLACENTAL ALLOGRAFTS AND METHODS OF MAKING THEREOF.

Key Points: 
  • POMPANO BEACH, Fla., May 06, 2024 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental derived allografts for advanced wound care, today announced that the United States Patent and Trademark Office (USPTO) has granted the Company’s request for Prioritized Examination for its application for U.S. Patent 18/290,914 titled STERILE HUMAN PLACENTAL ALLOGRAFTS AND METHODS OF MAKING THEREOF.
  • “This patent relates to our proprietary BioREtain® processing, which is at the root of our product technology, what differentiates us from our competitors, and ultimately what helps support wound care treatment for patients.
  • We look forward to working with the USPTO as our application undergoes priority examination.”
    Once granted, the patent will protect BioStem’s method of processing human amniotic tissue.
  • The global wound care dressing market was valued at $14.20 billion in 2023 and is projected to grow at a CAGR of 4.16% from 2024 to 2030.

SKYX Collaborates with World Leading Chinese Lighting Supplier and Manufacturer for the US, Chinese, and European Markets as it Continues to Enhance its Market Penetration

Retrieved on: 
Thursday, April 25, 2024
Collaboration, Growth, Lighting, Partnership, General Electric

MIAMI, April 25, 2024 (GLOBE NEWSWIRE) -- SKYX Platforms Corp. (NASDAQ: SKYX) (d/b/a SKYX Technologies) (the "Company" or "SKYX"), a highly disruptive smart platform technology company with more than 90 issued and pending patents globally and over 60 lighting and home décor websites, announces a new collaboration with a world leading Chinese lighting supplier and manufacturer Ruee Appliances for the US, Chinese, and European Markets. The collaboration provides SKYX substantial backing in several areas including financial, mass production manufacturing capabilities, and distribution to global markets.

Key Points: 
  • The collaboration provides SKYX substantial backing in several areas including financial, mass production manufacturing capabilities, and distribution to global markets.
  • The collaboration agreement introduces operational and logistical efficiencies and is expected to substantially enhance gross margins on SKYX’s product sales.
  • SKYX’s technologies make homes and buildings advanced, smart, and safe creating significant value for property developers and homeowners.
  • The company continues to enhance its market penetration for both retail and professional segments through its global ecommerce platform of more than 60 websites for lighting and home décor.

BioStem Technologies to Present at the 2024 Planet MicroCap Showcase

Retrieved on: 
Thursday, April 25, 2024
Planet, Regenerative medicine, OTC, Paris Las Vegas, PST

POMPANO BEACH, Fla., April 25, 2024 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental derived biologics for advanced wound care, today announced that it will present at the Planet MicroCap Showcase: VEGAS 2024 held at the Paris Hotel & Casino, in Las Vegas, NV., from April 30 - May 2 2024.

Key Points: 
  • POMPANO BEACH, Fla., April 25, 2024 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental derived biologics for advanced wound care, today announced that it will present at the Planet MicroCap Showcase: VEGAS 2024 held at the Paris Hotel & Casino, in Las Vegas, NV., from April 30 - May 2 2024.
  • BioStem’s Chief Executive Officer, Jason Matuszewski, will present on Wednesday, May 1, 2024 at 11.30 am PST, and will discuss the company’s expected milestones and growth strategy for 2024.
  • The 2024 Planet MicroCap Showcase will combine company presentations with educational panels and 1:1 meetings.
  • The event will bring together the best investors and thought leaders in MicroCap, and high quality MicroCap investing opportunities.

BioStem Technologies Inc. Completes Two-Year Audit, Prepares for Uplisting to Senior Exchange

Retrieved on: 
Wednesday, April 24, 2024
Medtech, CMS, OTC, Security (finance), DFU, Defense, Regenerative medicine, Ulcer, Clinical trial, Growth, Pharmaceutical industry

This completion is a significant step in the company’s strategy to uplist to a senior stock exchange.

Key Points: 
  • This completion is a significant step in the company’s strategy to uplist to a senior stock exchange.
  • The successful audit is a strategic move toward uplisting to a senior exchange, which the company anticipates will help to further validate its market position, attract a broader investor base, and enhance shareholder value.
  • Jason Matuszewski, CEO of BioStem Technologies, stated, "Completing this rigorous two-year audit underscores our dedication to transparency and regulatory compliance.
  • 2023 was a pivotal year for BioStem, marked by robust revenue growth, particularly in Q4, establishing a solid foundation for the company's future expansion.